Bristol-Myers recalls Coumadin blood thinner

May 02, 2011

(AP) -- Bristol-Myers Squibb Co. says it is recalling one production lot of its blood thinner Coumadin after finding an oversize tablet.

The company says it tested a returned bottle of Coumadin and found that one tablet was more potent than expected. An excessive dose of Coumadin, or , could create an increased risk of bleeding. The recall affects 5-milligram Coumadin tablets with an expiration date of Sept. 30, 2012. The production lot is number 9H49374A.

The New York drugmaker says patients taking 5-milligram tablets should not stop taking them, but should talk to their pharmacist to find out if their prescription was filled with that have been recalled.

Explore further: Italy bans Novartis flu vaccine after suspicious deaths

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study: New blood thinner works as well as Coumadin

Nov 15, 2010

(AP) -- A study finds that a new and easier-to-use blood thinner prevents strokes in people with a common heart rhythm problem as well as Coumadin does, and without an increase in bleeding or side effects.

Microsoft to release a tablet OS in 2012

Mar 04, 2011

(PhysOrg.com) -- Microsoft has finally decided to join the tablet OS market. Following in the grand tradition of Kinect (motion controls for video games, which came out after the Nintendo Wii sported them) ...

How does the color of a pill affect its efficacy?

Nov 15, 2010

According to recent research the color, shape, taste and even name of a tablet or pill can have an effect on how patients feel about their medication. Choose an appropriate combination and the placebo effect gives the pill ...

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.